Usage of Inhaled Nitric Oxides in Cases of Eisenmenger Syndrome

Neny Triastuti 1 *, Muhammad Perdana Airlangga 2, Muhammad Anas 3

1Department of Pharmacology, Medical Faculty of University Muhammadiyah of Surabaya 60113, Indonesia
2Department of Cardiology, Medical Faculty of University Muhammadiyah of Surabaya 60113, Indonesia
3Department of Obstetric Gynecologic, Medical Faculty of University Muhammadiyah of Surabaya 60113, Indonesia

ABSTRACT

Eisenmenger Syndrome is congenital heart disease with pulmonary hypertension and shunting from right to left turning. Pulmonary vascular resistance defects cause enlargement of the pulmonary arteries, as well as enlargement of the left ventricle. Hypoxia alveoli cause reversible vasoconstriction which increases the pressure of the pulmonary wedges. Physiological effects of inhaled nitric oxide therapy result in selective pulmonary vasodilation such that the pulmonary wedge pressure can be reduced. Although it does not affect the cardiac output and systemic arterial pressure. Inhaled nitric oxide in the pulmonary vascular is selective as it is activated by hemoglobin; selective vasodilatation in the ventilated region, local hypoxia alveoli constricts the surrounding vascular tissue and redistributes better and higher intraalveolar oxygen pressure to the ventilated lungs. Inhaled nitric oxide improves this process by increasing blood flow into a well-ventilated lung; bronchodilators; pulmonary surfactant; combining high concentrations of inspired oxygen with high concentrations of inhaled nitric oxide reduces minimum surface tension.

Keywords: inhalation nitric oxides, Eisenmenger syndrome, pulmonary vascular

Introduction

Research on Nitric Oxide (NO) continues to grow since the identification of this molecule in 1987 has the same effect as the endothelium-derived relaxing factor (EDRF) [1]. Many views about the mechanism of action of NO were put forward, since the application of inhaled nitric oxide (INO) in the laboratory and patients with primary pulmonary hypertension in 1991. In children and adults who experience severe pain and hypoxemia, INO improves arterial oxygenation and decreases pulmonary arterial hypertension selectively [2]. The combination of INO with a ventilator can reduce the need for extracorporeal membrane oxygenation (ECMO) [1, 3-7].

Eisenmenger Syndrome (ES) is congenital heart disease with pulmonary hypertension and shunting turning from right to left (R-L). The prevalence is around 7% in adulthood. And more in women than in men. His life expectancy decreased significantly, and few reached the age of 40 or 50 years. The cause of ES death is right ventricle failure and hypotension which causes cardiogenic shock [8-11].

Management of ES is with oxygen, vasodilators, anticoagulants, and phlebotomy. Furthermore, surgery if pulmonary vascular resistance is less than systemic vascular resistance. Cardiopulmonary transplants offer new hope [8-11].

In cyanotic congenital heart disease that persists into adulthood, decreased blood vessel resistance causes an increase in R-L shunting by increasing cyanosis. Decreased oxygenation causes impaired growth in the fetus. In ES with
secondary pulmonary hypertension or in primary pulmonary hypertension, decreased peripheral resistance when associated with decreased preload induced by changes in position or bleeding during labor will cause hypotension. It causes the right ventricle, unable to maintain blood flow through pulmonary arteriolar tissue with high resistance. Circumstances that cause extensive thrombosis in small blood vessels in the pulmonary arterial system that occur in the postpartum period also cause increasingly severe pulmonary hypertension [11-14].

This Literature review is intended to provide an overview of the use of nitric oxide which has an effect on local blood vessels in the lungs in patients with congenital heart disease with defects in the heart wall both in the ventricles and atria which cause blood shunting from right to left.

Physiological Effects of INO Therapy

The physiological functions of INO therapy for the cardiorespiratory system include the following:
1. Selective pulmonary vasodilation
   a. Hypoxia alveoli
   Hypoxia alveoli cause reversible vasoconstriction, thereby increasing pulmonary wedge pressure. Inhaled nitric oxide lowered it. Moderate cardiac output and systematic arterial pressure are not affected [1,2,9,10,17]. Selective in pulmonary because it is activated by hemoglobin [1,8,10].
   b. Selective vasodilation in ventilated areas
   Local alveolar hypoxia constricts the surrounding blood vessel tissue and redistributes blood flow to a better-ventilated lung and higher intraalveolar oxygen pressure. Inhaled nitric oxide enhances this mechanism by increasing blood flow through a well-ventilated lung [1,2,8,10,17].
2. Bronchodilators [1,17].
3. Pulmonary surfactants
   The combination of high concentrations of inspired oxygen and high concentrations of INO reduces the minimum surfactant surface tension in newborn pigs [1,18].

Effectiveness of INO

There are several known constraints related to the use of INO therapy. To increase the effectiveness of INO therapy, a strategy is needed to overcome these obstacles.
1. Hyporesponsiveness to INO
   The mechanisms are (a) the presence of endogenous NO, (b) the catecholamine effect on sepsis, (c) decreased pulmonary cyclic Guanine Mono Phosphate in sepsis, (d) increased vascular superoxide (O₂*), (e) decreased cGMP plasma, and (f) ABO (genetic) blood type, where A/O blood group has a more significant increase in the PaO₂/FiO₂ value. The incidence rate ranges from 30-45% [1,19].
2. Strategies to increase responses to INO (1)
   a. Phosphodiesterase inhibitors
   b. Almitrine infusion
   c. Inhibition of vascular superoxide production
   d. Partial liquid ventilation
Slide Effects of INO

Many benefits can be obtained by using INO as a therapeutic modality. Besides that, several things need to be monitored for several things related to INO therapy:
1. Be careful of left ventricular disorders, which can cause pulmonary edema [1,4].
2. The sudden termination of INO causes a withdrawal [1,4,20].
3. Bleeding time in ARDS (acute respiratory distress syndrome), INO decreases platelet aggregation and agglutination (in vitro). In vivo, studies were not affected [1,4,20].

Slide Nitric Oxide Toxicity

Toxicity that needs attention is [1,4,9,10,18,21,22].
1. NO2 formation.
2. Cellular toxicity
   For that, we need an INO security monitor with [1,22]:
   1. Levels of NO and NO2.
   2. Monitor device calibration.
   3. Methemoglobin levels.
   4. Use of certified tanks.
   5. Use of low concentrations

Eisenmenger Syndrome

Definition and Prevalence

Eisenmenger Syndrome (ES) is congenital heart disease with pulmonary hypertension and shunting turning from right to left (R-L). It is around 7% in adulthood and more in women [9,11,23,24].

Cardinal Signs

Pulmonary artery pressure is almost the same as systematic pressure. Bidirectional shunting or R-L. Pulmonary vascular resistance to more than 7.5 mmHg/L/min. The right ventricle and pulmonary artery always enlarge [8,11].

Cardinal Signs

1. Symptoms and Signs
   Symptoms that appear are tight and blue since the baby. Complaints of tightness vary with the development of age, hemoptysis, chest pain palpitations, and fainting attacks since adolescents and young adults. History of pneumonia, heart failure, eating disorders, susceptible to frequent infections in L-R but not in R-L [8,11,24]

   While the signs are cyanosis, sugar cane fingers, a wave that is prominent in jugular venous pulsation, the heart is not too enlarged and calm, the right ventricle lifts. The closure of the pulmonary valve is palpable. There is a systolic ejection click followed by a short systolic ejection murmur. A loud second heart sounded. Also, early diastolic murmurs. Signs of heart failure are rare, but cyanosis and polycythemia are common [8,11,23].

   Pneumonia, heart failure, eating disorders, susceptible to frequent infections in L-R but not in R-L.

2. Diagnostic Aids

   Electrocardiography shows right ventricular hypertrophy. The thorax looks like a trunk and the main branches of the enlarged pulmonary artery. Heart slightly enlarged. Hematocrit to assess the progression of the disease. Echocardiography sees the shunting site. Cardiac catheterization to establish the diagnosis and show that pulmonary artery pressure and pulmonary vascular resistance increase. Measurement of pulmonary wedge pressure is critical to determine whether the lesion can be corrected or not [8,23,24].

Differential Diagnosis

It must be distinguished from pulmonary hypertension due to lesions obtained from increased left atrial pressure. Primary pulmonary hypertension and thromboembolic pulmonary hypertension must be excluded. A history of murmurs and cyanosis since children is beneficial in identifying congenital lesions. In severe pulmonary hypertension can open the foramen ovale and cause R-L shunting, causing misdiagnosis of congenital lesions. Peripheral pulmonary artery stenosis also causes physical signs of increased primary pulmonary arterial pressure [8,11,2-25].

Complications

Complications include progressive polycythemia and pulmonary thromboembolism. Pulmonary infarction and bleeding from plexiform angiomatous lesions around the pulmonary artery. With the presence of polycythemia, there is a tendency to bleeding a lot. If Hct (hematocrit) is more than 60% easy to bruise, bleeding gums,
petechiae, and hemoptysis. Endocarditis and arteria can occur [8,11,23,24]

Management
1. Medical Management
   • Supportive Therapy
     Therapy for patients with Eisenmenger Syndrome previously focused solely on palliative therapy or heart-lung transplantation [11,26]. The long-term supply of oxygen is controversial. Nighttime oxygen delivery with a 2-year follow-up period did not affect functional capacity, disease course, and patient survival [27,28]. Oxygen delivery needs to be considered in cases where oxygen administration causes an increase in oxygen saturation and decreased symptoms [8,11,23-25,28].

     Patients with Eisenmenger Syndrome with hyperviscosity associated with increased erythrocyte production can be performed phlebotomy with isovolumic fluid replacement, usually hematocrit > 65% [26]. However, routine phlebotomy should be avoided because it causes anemia, disruption during exercise, decreased quality of life, and an increased risk of thromboembolic events [8,11,23-25,27].

      • Medicinal Therapy
         Giving diuretics can be given to patients with Eisenmenger Syndrome with congestive symptoms, but has a risk of hyperviscosity [11,26].

         Anticoagulants in Eisenmenger Syndrome must be given with caution, given the risk of hemoptysis, stroke, and bleeding. Coumarin-derived anticoagulants are still acceptable but limited to atrial fibrillation, intracardiac mechanical prosthesis, and advanced heart failure [8,11,23,25,29,30,31].

         The use of Calcium channel blockers in patients with Eisenmenger Syndrome is not recommended because it can reduce systemic arterial pressure and increase right to left shunting, which causes syncope and sudden death [11,26].

         Endothelin Receptor Antagonist (ERA). Endothelin-1 plays a role in the structural and functional abnormalities of pulmonary arteries. There are three types of approved ERA groups, namely bosentan, macitentan (dual-ERA), and ambrisentan (mono-ERA). Bosentan is a dual endothelin receptor oral antagonist preparation that functions to reduce pulmonary vascular pressure and resistance, reduce the incidence of inflammation and vascular fibrosis on long-term observation [27,20]. The BREATH-5 study (Bosentan Randomized Trial of Endothelin Antagonist Therapy-5), showed that bosentan in patients with Eisenmenger Syndrome with a functional WHO class III reduced Pulmonary Vascular Resistance (PVR) significantly and improved exercise capacity compared to placebo [26,29,30-32]. The ESC guidelines currently support giving Bosentan as the first choice for sufferers of functional class III-IV Eisenmenger syndrome [27,31]. The side effects are headache, facial flushing, and nasopharyngitis. The provision of ERA requires routine blood test monitoring because it can induce anemia and liver disorders [11,27,28].

         Phosphodiesterase Type 5 Inhibitors. Oral PDE-5 inhibitors have several benefits, namely increasing vasodilatation of Nitric Oxide (NO) by increasing cGMP concentrations, having antiproliferative effects of vascular smooth muscle cells, and increasing contractility of right ventricular hypertrophy [11,30].

         SUPER-1 research (Sildenafil use in Pulmonary Arterial Hypertension) shows that Sildenafil can improve exercise capacity in pulmonary arterial hypertension. Also, it has a short-term safety and efficacy profile. Sastry et al. Prove that the administration of sildenafil for four months is comparable to that observed in the SUPER-1 study [11,30].

         Zhang et al. study of 168 patients with Eisenmenger Syndrome who were treated with sildenafil for one year showed improvement in pulmonary hemodynamics. Mukhopadhyay et al. research showed 16 Eisenmenger sufferers treated with tadalafil experienced a decrease in PVR, mean PAP, and increased oxygen saturation for 12 weeks [11,31,33].

         The risk of liver damage is not found in patients with Eisenmenger Syndrome who are treated with PDE-5 oral inhibitors and thus do not require routine blood tests [11,27]. Prosta-
cyclooxyn Analogs. Preparations in the analog prosta
cyclin group, among others epoprostenol, have the most potent effect and can only be
given intravenously continuously because of the short half-life of only a few minutes, but can be at risk of long-term paradox embolism and sepsis [24,27]. The administration of intravenous epoprostenol increased functional capacity, oxygen saturation and exercise capacity significantly in 8 sufferers of ES after three months of therapy [11,26].

Trexprostinil is also a prostacyclin analog with a half-life of 3 hours, can be used subcutane
eously and intravenously. Long-term use of treprostinil provides the same survival benefits as intravenous epoprostenol [11,24,28]. Beraprost is an oral prostacyclin analog. In randomized controlled trials, it was found not to show a significant effect. During the initial phase of treatment, the administration of beraprost shows little progression lasting up to 6 months. Nevertheless, after one year, there is no longer a difference between the beraprost and the placebo group. Beraprost does not play an essential role in the treatment of PAHs associated with congenital heart disease and Eisenmenger Syndrome, so it is no longer used in Europe (28); (30). Prostacyclin analogs are included in the second or third line in the treatment algorithm for pulmonary hypertension [11,24,27].

Combination Therapy
The use of combination therapy can be con
cidered in patients with symptomatic ES who do not improve on first-line drug therapy but need to be vigilant because of unknown interactions that cause toxicity. Giving sildenafil and bosentan combination therapy in 21 patients with ES, a significant increase of 6 MWD, PVR, and pulmonary blood flow compared with placebo [11,26,34].

Surgical Management
If pulmonary vascular resistance is equiva
lent to systematic and little or no L-R shunting, closure of intracardiac defects or extracardiac defects is contraindicated. Cardiopulmonary transplantation gives new hope [8,11,25,35].

Prognosis
Life expectancy decreased significantly, and few reached the age of 40 or 50 years. The cause of death in ES is right ventricular failure and hypotension which causes cardiogenic shock [8,10,11,23,24,25]. Maternal mortality in the presence of ES reported as 30–50% and pregnancy should be avoided [36].

Conclusion
Eisenmenger Syndrome is congenital heart disease with pulmonary hypertension and shunting turning from right to left. The prevalence is 7% in adulthood. More occur in women. The life expectancy of people with ES has decreased significantly, and few reach the age of 40 or 50 years. The cause of death is a ventricu
lar failure due to hypotension, which causes cardiogenic shock.

Management of patients with ES is oxygenation, anticoagulants, vasodilators, and phlebotomy. Surgery is only performed if pulmo
nary vascular resistance is less than systemic vascular resistance. Cardiopulmonary transplan
tation provides new hope for sufferers.

In cyanotic congenital heart disease that persists into adulthood, decreased blood vessel resistance causes an increase in R-L shunting by increasing cyanosis. Decreased oxygenation causes impaired fetal growth. Eisenmenger Syndrome with secondary pulmonary hyper
tension or primary pulmonary hypertension, decreased peripheral resistance when associ
ated with decreased preload induced by changes in position or bleeding during labor will cause hypotension. This condition causes the right ventricle not to be able to maintain blood flow through pulmonary arteriolar tissue with high resistance. Also, the conditions that cause extensive thrombosis in the pulmonary artery's small vessel system postpartum cause severe pulmonary hypertension.

Inhalation nitric oxide is a potent and selec
tive pulmonary vasodilator. In ES, relaxation of the endothelium-dependent pulmonary blood vessels is disturbed. Patients with ES who inhale NO can directly reduce pulmonary hyper
tension and increase oxygenation due to the optimization of the ventilation-perfusion rela
tionship. Inhalation nitric oxide also has an antithrombotic effect and is also used in preparation for a pulmonary heart transplant.

References
5. Chen C (1997) Nitric Oxide For Newborns Nitric Oxide Proves Effective In Treating Newborns With Life-Threatening Lung Disorder [Internet]. Available from: cwchen@ITSA.UCSF.EDU


